Skip to content

Measurement of the Folate Receptor in Blood

Measurement of the Folate Receptor in Blood

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00838747
Enrollment
7
Registered
2009-02-06
Start date
2008-09-30
Completion date
2011-07-31
Last updated
2016-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

folate receptor, blood samples, ovarian cancer, development of measure of folate receptor in blood samples, possible selection of patients for treatment with FR targeted agents

Brief summary

The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to achieve anti-tumour efficacy whilst reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. One such drug BGC 945 is currently being tested in preclinical study at The Institute of Cancer Research

Detailed description

A method has been developed in the laboratory which has been able to measure FR obtained from cancer cells in culture that has been added into blood. We would like to study if this method can measure FR in plasma and serum obtained from patients with ovarian cancer. We would also like to analyse plasma and serum samples obtained from healthy volunteers to determine if they have any appreciable levels of FR, which can then be compared to the measurements obtained from cancer patients.

Interventions

None listed

Sponsors

Royal Marsden NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with stage III/IV ovarian cancer * healthy volunteers who are staff at the ICR and RMH

Exclusion criteria

* patients or healthy volunteers who are unable to give informed consent * pregnancy

Design outcomes

Primary

MeasureTime frame
To measure the levels of folate receptor in blood samples obtained from patients with ovarian cancer and from healthy volunteers1 year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026